Viscosupplementation Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Viscosupplementation Market Trends and Insights

Ageing-Linked OA Prevalence Surge

Worldwide osteoarthritis cases climbed to 607 million in 2021, with knee disease making up more than 56% of the burden. The age-standardized prevalence rate^{[1]Zihao Wang, “Global, regional and national burden of osteoarthritis in 1990–2021: a systematic analysis of the global burden of disease study 2021,” BMC Musculoskeletal Disorders, bmcmusculoskeletdisord.biomedcentral.com} rose from 6,393.1 to 6,967.3 per 100,000. Obesity contributes approximately 4.43 million disability-adjusted life years, amplifying joint degeneration severity. Health-economic analyses show viscosupplementation delays knee arthroplasty and lowers lifetime treatment expense, positioning the therapy as a fiscal lever for payers coping with an ageing base.

Shift to Single-Injection HA Regimens

Randomized trials confirm that single-injection hyaluronic acid provides pain relief comparable to multi-dose courses while reducing clinic visits. FDA clearance of Monovisc, the first single-injection, non-animal product, accelerated adoption. Yet head-to-head studies^{[2]Selim Safali, “Evaluation of single and multiple hyaluronic acid injections at different concentrations with high molecular weight in the treatment of knee osteoarthritis,” BMC Musculoskeletal Disorders, bmcmusculoskeletdisord.biomedcentral.com} show three low-dose injections can yield better functional scores than one high-dose shot. Manufacturers are therefore raising molecular weight to prolong residence time, aiming to reconcile convenience with peak efficacy.

Product Approvals & Reimbursement Expansions

Recent FDA clearances, such as Hymovis, underscore regulators’ focus on demonstrable clinical outcomes over bioequivalence alone. U.S. payers now reimburse distinct HA codes J7318-J7329, although prior-authorization rules have tightened. The 2025 Physician Fee Schedule^{[3]Centers for Medicare & Medicaid Services, “Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments,” federalregister.gov} revises practice-expense RVUs, influencing provider margins. Companies with robust evidence portfolios enjoy smoother market entry, whereas products lacking comparative data face formulary pushback.

Fermentation-Based Vegan HA Supply Scalability

Engineered Streptococcus zooepidemicus fermentation now yields up to 4.38 g/L hyaluronic acid through refined precursor balance and gene-expression control. This route avoids animal-derived raw materials and reduces exposure to H5N1 supply shocks. It also lets producers tailor ultra-high molecular weight grades^{[4]Filippo Migliorini, “Comparison of Different Molecular Weights of Intra-Articular Hyaluronic Acid Injections for Knee Osteoarthritis: A Level I Bayesian Network Meta-Analysis,” Biomedicines, mdpi.com} that clinical meta-analyses associate with superior pain relief. Marine by-products, such as mussel wastewater substrates, present additional feedstock options, deepening supply resilience.

Clinical-Efficacy Debate & Payer Push-Back

The American College of Rheumatology and the American Academy of Orthopaedic Surgeons classify viscosupplementation evidence as limited, fueling insurer caution. Meta-analyses show high study heterogeneity, allowing payers to impose step-therapy criteria that favor NSAIDs or corticosteroids first. Platelet-rich plasma now records stronger long-term results in several trials, prompting coverage committees to revisit HA reimbursement. Providers must compile detailed conservative-treatment histories to secure payment, elevating the administrative load.

FDA Device-to-Drug Reclassification Risk

Following the Genus court ruling, FDA signaled plans to re-evaluate hyaluronic acid’s device status, which could trigger costlier, drug-style trials and longer review clocks. The prospect complicates R&D budgeting and may advantage larger pharma players able to fund phase III programs. Firms thus maintain dual dossier strategies to hedge against final classification outcomes.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Dosage: Single-Injection Convenience Drives Adoption

Single-injection products captured 45.72% of the viscosupplementation market share in 2025 and command a 9.41% CAGR to 2031. The Viscosupplementation market size tied to single-dose regimens is forecast at USD 3.38 billion in 2031. The popularity stems from reduced clinic time and lower procedural fees. Three-injection courses retain relevance for patients needing incremental symptom control, while five-shot regimens serve severe bilateral disease. 

Clinical data show concentrated cross-linked preparations sustain symptom relief over 60 days. Ongoing formulation work seeks to match the functional gains of multi-dose protocols by boosting viscoelasticity and residence time of single shots. Manufacturers exploit this clinical tension to position premium high-molecular-weight brands at the intersection of convenience and efficacy.

By Product Source: Fermentation Gains Ground Despite Avian Dominance

Avian sources held 53.65% of the viscosupplementation market size in 2025, thanks to decades of clinical familiarity. However, fermentation products grow 9.32% annually as the Viscosupplementation market prioritizes supply security and vegan labelling. The Viscosupplementation market size for non-avian HA is projected to reach USD 3.42 billion by 2031. 

Process innovation allows bespoke molecular-weight spectra without the viral-contamination risks linked to rooster comb extract. Companies hedge by running parallel avian and fermentation lines, but long-range capex tilts toward fermenters located in China and South Korea, where feedstock and utilities cost less.

By Application Site: Knee Dominance Masks Emerging Opportunities

Knee injections delivered 73.88% revenue in 2025, representing the largest slice of the viscosupplementation market share. Others segment pace the field at a 10.12% CAGR.

Ultrasound guidance now enables accurate hip access under local anesthetic, improving patient tolerance and expanding referral volumes. In the shoulders, viscosupplementation eases glenohumeral stiffness in seniors unable to undergo arthroplasty. As device makers roll out narrow-gauge needles and portable imaging, orthopedists broaden HA use beyond knees, seeding new revenue layers.

By End-User: ASCs Capitalize on Efficiency Trends

Hospitals held 41.74% of the viscosupplementation market share in 2025, yet ambulatory surgical centers (ASCs) record a 9.69% CAGR through 2031, the fastest among care settings. 

ASC growth rides on bundled-payment models that reward lower facility fees and same-day discharge. Portable ultrasound lowers setup cost, letting clinics perform injections in procedure rooms rather than fluoroscopy suites. Orthopedic and sports medicine offices occupy a middle ground, retaining loyal athlete populations while referring complex geriatric cases back to hospital groups.

Geography Analysis

North America contributed 41.45% of the viscosupplementation market share in 2025 and is forecast to grow at 8.98% CAGR until 2031. HCPCS codes J7318-J7329 assure reimbursement continuity, but payers are tightening prior-authorisation rules that lengthen approval cycles. FDA product clearances sustain pipeline momentum, yet looming device-to-drug reclassification could inflate compliance spending, particularly for smaller entrants. Distribution partnerships, such as the renewal between Anika Therapeutics and Pendopharm that extends to 2030, reinforce market depth. 

Asia-Pacific registers the top 9.58% CAGR, driven by urban hospitals adopting minimally invasive pain procedures and by domestic HA producers scaling fermentation capacity. Government import-substitution policies in China and India nudge buyers toward local brands, trimming landed cost. Rising life expectancy and joint-disease prevalence in Japan and South Korea sustain demand even in mature payer environments. 

Europe advances at 8.66% CAGR under the strict EU Medical Devices Regulation that mandates post-market performance studies. The paperwork burden weeds out small labelers, handing advantage to well-capitalised suppliers. Middle East & Africa follow at 8.51% CAGR on the back of hospital expansion in Gulf Cooperation Council states, whereas South America trails at 8.07% due to fiscal austerity and uneven insurance penetration. Collectively, emerging regions form the next frontier once regulatory clarity and payer frameworks solidify.

Regulatory Landscape

Viscosupplementation products for intra-articular injection are mainly regulated as high-risk medical devices. In the United States, FDA oversight runs through Premarket Approval (PMA) pathways, while Europe is governed by Regulation (EU) 2017/745 (EU MDR) and related conformity assessment through notified bodies. In the United States, lifecycle changes often proceed via PMA supplements, including FDA approvals in May 2025 for Euflexxa manufacturing-capacity expansion (PMA supplement) and for Channel-Markers Medical to add an alternate bulk sodium hyaluronate supplier for TriVisc and GenVisc 850 (PMA supplement), which keeps manufacturing controls and raw-material change documentation central.

Quality and clinical-evidence expectations are also moving tighter through system-level updates and MDR implementation. The FDA implemented the Quality Management System Regulation (QMSR) in February 2026, bringing device quality systems closer to ISO 13485:2016 and raising compliance expectations across design controls, supplier management, and post-market processes. In Europe, MDR-related updates continued as the European Commission adopted Delegated Regulation (EU) 2026/1451, while EMA and EU expert-panel processes maintain scrutiny of clinical evaluation for higher-risk device categories. That combination keeps barriers elevated for smaller labelers and sustains the importance of post-market performance data.

Value Chain Analysis

The value chain starts with pharmaceutical-grade sodium hyaluronate production, sourced from avian tissue extraction or, increasingly, from bacterial fermentation, commonly Streptococcus zooepidemicus, to reduce exposure to avian biosecurity shocks and protein or viral impurity risks. Upstream steps include purification, molecular-weight control, and, for longer-acting products, chemical modification or cross-linking using specialized reagents. Midstream manufacturers then execute aseptic formulation, prefilled syringe filling, terminal sterilization or sterility assurance, and quality release under medical device quality systems aligned with ISO 13485, reinforced by the FDA QMSR shift implemented in February 2026.

Downstream, products reach customers through direct sales forces, specialty distributors, and centralized procurement by hospital groups and ambulatory surgical centers that manage inventory and reimbursement workflows. Cold-chain handling (commonly 2-8 degrees Celsius) and shelf-life constraints favor established distribution networks, while reimbursement administration and prior authorization create friction at the point of care. Regulatory maintenance and manufacturing continuity also remain part of the operational chain, as reflected in recent FDA PMA supplements for manufacturing changes and raw-material supplier additions, such as the May 2025 approvals tied to Euflexxa capacity and Channel-Markers Medical supplier flexibility.

Market Opportunities and Future Outlook

Single-injection regimens continue to represent a key commercial whitespace, since they reduce clinic visits while the evidence debate persists around comparative outcomes versus multi-injection courses. Evidence generation remains a direct input into product positioning and protocol standardization, including a clinical trial initiated in January 2026 at University of Erlangen-Nurnberg Medical School (NCT07352540) that compares single-shot versus triple-shot hyaluronic acid protocols. Guideline and consensus work is also shaping uptake, with ESCEO convening a working group in January 2025 to update evidence on intra-articular hyaluronic acid, which gives a near-term lever to manufacturers that can support stronger comparative data packages.

Portfolio expansion is also being pursued through chemistry and combination strategies that differentiate beyond molecular weight alone, including linear versus cross-linked (chemically modified) constructs and co-formulations or co-injection approaches with non-HA agents. Recent actions provide concrete entry points, including FDA PMA for HYMOVIS ONE in April 2025, followed by its US commercial launch in January 2026 and visibility at AAOS in 2026, which supports a path for new premium single-injection offerings. On the supply side, FDA acceptance of manufacturing and sourcing changes, such as the May 2025 approvals tied to capacity expansion and alternate bulk sodium hyaluronate suppliers, supports resilience initiatives and widens the addressable scope for non-avian and multi-sourced HA supply strategies.